1-3 of 3
Joseph G. Jurcic
Close
Sort by
Journal Articles

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1 -mutated AML

Clinical Trials & Observations
Stéphane de Botton, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H. Wei, Pau Montesinos, David C. Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K. Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin M. Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge Cortes
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3117–3127.
https://doi.org/10.1182/bloodadvances.2022009411
Published: 2023
Includes: Supplemental data
Journal Articles

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

Clinical Trials & Observations
Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J. Cook, Philippe Rousselot, David A. Rizzieri, Jane L. Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Joseph G. Jurcic, Mikkael A. Sekeres, Michael R. Savona, Gail J. Roboz, Dale Bixby, Kate Madigan, Angela Volkert, Kristin Stephens, Qing Kang-Fortner, Kristen Baker, Sofia Paul, Michael McKeown, John Carulli, Matthew Eaton, Graeme Hodgson, Christopher Fiore, Michael J. Kelly, David A. Roth, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1858–1870.
https://doi.org/10.1182/bloodadvances.2022008806
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia

Clinical Trials & Observations
Peter G. Maslak, Tao Dao, Yvette Bernal, Suzanne M. Chanel, Rong Zhang, Mark Frattini, Todd Rosenblat, Joseph G. Jurcic, Renier J. Brentjens, Maria E. Arcila, Raajit Rampal, Jae H. Park, Dan Douer, Laura Katz, Nicholas Sarlis, Martin S. Tallman, David A. Scheinberg
Journal: Blood Advances
Blood Adv (2018) 2 (3): 224–234.
https://doi.org/10.1182/bloodadvances.2017014175
Published: 2018
Includes: Supplemental data